Aidoc vs Lunit (2026)
The enterprise acute platform against the cancer screening specialist. Aidoc runs detection across an imaging estate through an operating system handling normalisation, monitoring and governance, with a 2026 clearance covering many acute indications from one named foundation model. Lunit works cancer detection on chest radiographs and mammograms, with the deeper evidence base in screening populations and a listed parent behind it. They answer different questions on different clocks: acute triage is judged on time to treatment, screening on positive predictive value at your prevalence. A health system may run both in different departments, and the mistake to avoid is comparing them on sensitivity, which tells you nothing about either job.
- It runs many detection models across an imaging estate through an operating system handling normalisation, monitoring and governance for every model on it.
- The 2026 clearance covers a double digit set of acute indications from a single named foundation model, with regulator reviewed performance behind it.
- For a health system, the platform outlives whichever individual algorithms get replaced.
- Cancer detection across chest radiograph and mammography is the portfolio, with a listed parent and regulatory footprints in multiple markets.
- The evidence base in screening populations is deeper than most detection vendors, which is where specificity multiplies across a large healthy denominator.
- For a screening programme, a vendor built around cancer detection is the closer fit than an acute triage platform.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Aidoc and Lunit are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Aidoc its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Lunit, Aidoc grades higher on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Lunit its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Aidoc, Lunit does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Aidoc or Lunit?
The AI Health Index grades Aidoc higher than Lunit on every axis that separates them, several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Lunit does not grade higher on any scored axis.
Where do Aidoc and Lunit differ most?
The widest separation the AI Health Index records between Aidoc and Lunit is on Model Supply Chain Disclosure, where Aidoc grades A and Lunit grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Aidoc and Lunit grade the same?
The AI Health Index grades Aidoc and Lunit the same on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Aidoc and Lunit not disclosed?
At the last review, at least one of Aidoc and Lunit published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These operate on different clocks and their evidence is not interchangeable: an acute platform is judged on time to treatment while a screening product is judged on positive predictive value at your prevalence, and comparing them on sensitivity settles nothing. Neither publishes subgroup performance. Findings counts and indication counts are not comparable between vendors because each defines them differently, so ask both for performance on the findings your population actually presents with.